Status:

COMPLETED

Pain, Nutrition and Glycemic Response in Chronic Low Back Pain and Breast Cancer Survivors

Lead Sponsor:

Vrije Universiteit Brussel

Collaborating Sponsors:

KU Leuven

Conditions:

Chronic Pain

Eligibility:

FEMALE

18-65 years

Phase:

NA

Brief Summary

The development of chronic pain is one of the most seen sequelae in the cancer survivor population. Literature reports the presence of pain in approximately 40% of 5-year survivors. Specifically, in b...

Detailed Description

Study Design: This study will be carried out as an experimental, cross-over study, including two pain populations, one control group and two assessment sessions. At the first session, firstly, all p...

Eligibility Criteria

Inclusion

  • GROUP 1=Chronic Low Back Pain
  • Inclusion Criteria
  • Women between 18 and 65 years old;
  • Native Dutch speaker;
  • Experiencing chronic nonspecific low back pain (i.e. pain present for at least 3 months, at least 3 days per week);
  • No new medication or new treatments started in the 6 weeks prior to or during study participation;
  • Non-specific failed back surgery can be included if the operation was anatomically successful and happened at least 3 years ago;
  • No physical exertions over 3 Metabolic Equivalent of Task (MET) in the 3 days before the assessments;
  • No analgesics/ caffeine/ alcohol/ nicotine 48 hours prior to the assessments
  • Exclusion Criteria
  • People who have any other diagnosed systemic diseases e.g. diabetes mellitus, hypertension, cardiovascular diseases etc;
  • Participants who have neuropathic pain according to "Douleur Neuropathique 4 Questionnaire" and the S-LANSS Neuropathic Pain Score;
  • Chronic widespread pain diagnosis (like fibromyalgia, chronic fatigue syndrome, whiplash);
  • Current pregnancy or pregnant in the past year;
  • Specific spinal pathology (e.g., hernia, spinal stenosis, spondylolisthesis, infection, spinal fracture or malignancy)
  • GROUP 2= Breast Cancer Survivors
  • Inclusion Criteria
  • Female breast cancer survivors with chronic pain (lasting at least 3 months, at least 3 days per week);
  • Participants between 18 and 65 years old;
  • Native Dutch speaker;
  • Active treatment ended at least 3 months ago (i.e. surgery, radiotherapy and chemotherapy; hormone and immune therapy can be going on);
  • No analgesics/ caffeine/ alcohol/ nicotine 48 hours prior to the assessments
  • Exclusion Criteria
  • People who have any other systemic disease like hypertension, Type II Diabetes etc;
  • Current pregnancy or pregnant in the past year;
  • Current active cancer process;
  • Tube feeding
  • GROUP 3= Healthy, Pain-Free Controls
  • Inclusion Criteria
  • Female, healthy and pain-free participants between 18 and 65 years old;
  • Native Dutch speaker;
  • No analgesics/ caffeine/ alcohol/ nicotine 48 hours prior to the assessments
  • Exclusion Criteria
  • Current pregnancy or pregnant in the past year;
  • People who have any other diagnosed systemic diseases e.g. diabetes mellitus, hypertension, cardiovascular diseases;
  • Participants who have neuropathic pain according to "Douleur Neuropathique 4 Questionnaire" and the S-LANSS Neuropathic Pain Score;
  • Chronic widespread pain diagnosis (like fibromyalgia, chronic fatigue syndrome, whiplash);
  • Specific spinal pathology (e.g., hernia, spinal stenosis, spondylolisthesis, infection, spinal fracture or malignancy)

Exclusion

    Key Trial Info

    Start Date :

    September 21 2020

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    December 19 2022

    Estimated Enrollment :

    121 Patients enrolled

    Trial Details

    Trial ID

    NCT04459104

    Start Date

    September 21 2020

    End Date

    December 19 2022

    Last Update

    April 19 2023

    Active Locations (2)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (2 locations)

    1

    Vrije Universiteit Brussel

    Brussels, Belgium, 1000

    2

    KU Leuven

    Leuven, Belgium, 3000